• BTC statutory profit after tax of $4.9m, up 199% YoY
• Consolidated revenue up 9% to $5.3m, gross profit up 6% to $2.3m
• Diversified business with new acquisitions and contract wins

BTC Health Ltd (ASX: BTC) has announced its half-year financial results for the 6 months ending 31 December 2024, along with a general business update. The company recorded a statutory profit after tax of $4.9m, up 199% compared to the same period last year. Consolidated revenue grew 9% to $5.3m, with gross profit increasing 6% to $2.3m. Operating expenses remained well controlled, rising only 4% to $2.1m. The company's EBITDA for the period was $0.2m, up 9% year-on-year. Key highlights include the acquisition of the Corcym heart valve business, which is expected to contribute an additional $3.6m in revenue on a full-year basis, and the award of a $5m, 5-year ECMO contract with the Royal Children's Hospital in Melbourne. The company's infusion pumps, Rhythmic and Elasto-Q, were also approved for private health reimbursement. Additionally, BTC Pharma extended its distribution partnership with Arna Pharma for the Aridol and Bronchitol products in Australia and New Zealand. The company is committed to delivering further improvements in its bottom-line performance for FY25, targeting a positive EBITDA and a clear pathway towards sustainable profitability.

BTC Health Ltd is targeting a positive EBITDA and establishing a clear pathway towards sustainable profit for the full year FY25.

The business continues to generate positive momentum and pursue double-digit growth across a more diversified product range. The company is committed to making further improvements in the bottom-line performance for FY25.